Essa Pharma Stock Price, News & Analysis

ESSA Pharma (NASDAQ: EPIX) has announced amendments to its Business Combination Agreement with XenoTherapeutics. Under the revised terms, ESSA shareholders are expected to receive approximately $0.12 per share in cash at closing, plus one non-transferable contingent value right (CVR) worth up to $0.14 per share.

The potential CVR payments represent up to $6.7 million in aggregate distributions to CVR holders, depending on contingent liabilities. This follows an initial cash distribution of approximately $1.69 per share made on August 22, 2025. The Special Meeting to approve the transaction has been adjourned to October 3, 2025, with XOMA Royalty (NASDAQ: XOMA) continuing as the structuring agent.

ESSA Pharma (NASDAQ: EPIX) announced the adjournment of its special meeting regarding the previously announced acquisition by XenoTherapeutics. The meeting, originally scheduled for September 10, 2025, will be postponed to September 29, 2025 at 2:00 PM Pacific Time.

The adjournment aims to allow continued discussions about the transaction terms, specifically focusing on ESSA's cash forecast and upfront cash distribution to shareholders. The meeting will be held virtually, and shareholders who have already voted need not take additional action. The British Columbia Supreme Court approval hearing, initially planned for September 12, 2025, will be rescheduled with the date to be announced later.

ESSA Pharma (NASDAQ: EPIX) has issued a clarification regarding the Nasdaq due bill trading period for its previously announced US$80 million cash distribution to shareholders. The distribution, which amounts to approximately $1.69 per share, was paid on August 22, 2025.

The company corrected its earlier announcement, stating that the due bill trading period ran from August 19 through August 22, 2025, not through August 25 as previously stated. The Common Shares began trading ex-dividend on August 25, 2025. This distribution is part of ESSA's business wind-up process related to its transaction with XenoTherapeutics, Inc.

ESSA Pharma (NASDAQ: EPIX) has announced key details regarding its previously disclosed US$80 million cash distribution to shareholders. The distribution, approximately $1.69 per share, is part of the company's business wind-up following its transaction with XenoTherapeutics.

The ex-dividend date is set for August 25, 2025, with payment scheduled for August 22, 2025. Due to the distribution's size (over 25% of share price), Nasdaq has implemented a "due bill" trading period from August 19-25, 2025. During this period, share trades will include the right to receive the distribution.

ESSA Pharma (NASDAQ: EPIX) has announced a significant US$80 million cash distribution to shareholders as part of its business wind-down process. The distribution is scheduled for August 22, 2025, with a record date of August 19, 2025.

This distribution precedes EPIX's pending transaction with XenoTherapeutics, a non-profit biotech company, which will acquire all outstanding common shares. The special meeting for this transaction is set for September 10, 2025. Shareholders are expected to receive approximately US$1.91 per share in total, combining the distribution and transaction proceeds, excluding potential contingent value rights payments.

ESSA Pharma (NASDAQ: EPIX) announced plans to seek court approval for two key orders related to its previously announced business combination with XenoTherapeutics. The company will apply to the Supreme Court of British Columbia on August 5, 2025 for an interim order to hold a special meeting and a distribution order to expedite cash distribution to shareholders.

The total cash distribution to shareholders is estimated at US$1.91 per Common Share, which includes both the initial cash distribution and cash payable upon transaction closing, excluding any contingent value rights payments. The court hearing will take place at 9:45 a.m. (Pacific time) at the Vancouver courthouse, with response materials due by July 31, 2025.

ESSA Pharma (NASDAQ: EPIX) has announced a definitive agreement to be acquired by XenoTherapeutics, with financing from XOMA Royalty Corporation (NASDAQ: XOMA). The all-cash transaction will provide EPIX shareholders with approximately $1.91 per common share, plus one non-transferable contingent value right (CVR) worth up to $0.06 per share payable within 18 months post-closing.

The transaction, expected to close in second half of 2025, requires approval from 66⅔% of ESSA shareholders and securityholders. The agreement includes a $2.5 million termination fee and customary deal-protection provisions. ESSA's board unanimously approved the transaction, with directors and senior officers, holding 2.23% of shares, agreeing to vote in favor.

ESSA Pharma (NASDAQ: EPIX) reported its fiscal Q2 2025 financial results, highlighting ongoing efforts to evaluate strategic options after discontinuing its prostate cancer clinical trials. The company recorded a net loss of $6.4 million, improved from $9.0 million in Q2 2024. R&D expenses decreased to $3.5 million from $6.2 million, while G&A expenses reduced to $3.9 million from $4.3 million year-over-year.

The company maintains a strong financial position with $113.9 million in cash and short-term investments and $113.5 million in net working capital as of March 31, 2025. ESSA is exploring various strategic alternatives, including potential mergers, acquisitions, or business combinations, while implementing cost reductions and headcount adjustments.

ESSA Pharma Inc. (NASDAQ: EPIX) held its Annual General Meeting of Shareholders on March 5, 2025. The company, which previously focused on developing prostate cancer therapies before discontinuing its clinical trials and development programs, announced key shareholder votes.

Shareholders approved setting the board size at seven directors and re-elected David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, and Sandy Zweifach. Additional approvals included the re-appointment of Davidson & Company LLP as auditors and a non-binding advisory vote on executive compensation.